Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

The researchers conducted a 68-week, double-blind, randomized, placebo-controlled trial at 61 sites in 11 countries.

The primary end points were the percentage change in body weight and the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score (on a scale of 0 to 100, with higher scores reflecting worse outcomes) from baseline to week 68.

A key confirmatory secondary end point was the physical-function score on the 36-Item Short Form Health Survey (SF-36), version 2 (on a scale of 0 to 100, with higher scores indicating greater well-being).

What Was Measured

Topics PubMed links to this paper include Body Mass Index, Combined Modality Therapy, Obesity, Osteoarthritis, Knee, Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists and Counseling.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (The New England journal of medicine), a journal based in United States.

More context: the Semaglutide compound page.